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Abstract We analysed the activity of the proximal promoters of
the K2 and K5 integrin genes in human keratinocytes. An AP-1
site, found in the K5 but not the K2 promoter, bound c-Jun/c-Fos
dimers and contributed strongly to promoter activity. Both
promoters had a CCAAT/enhancer binding protein (C/EBP)
binding site: the K5 C/EBP element enhanced activity, while the
K2 site was a negative regulatory element. C/EBP overexpres-
sion repressed the activity of both promoters, but the effect was
independent of occupancy of the identified C/EBP binding sites,
suggesting interactions with additional transcription factors. We
propose that upregulation of C/EBPs contributes to the inhibition
of integrin transcription during keratinocyte terminal differen-
tiation, while AP-1 factors play a role in the selective induction
of the K5 gene during wound healing. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The key role of cell^extracellular matrix adhesion in cellular
di¡erentiation is well illustrated in mammalian epidermis. Ad-
hesion is a negative regulator of keratinocyte di¡erentiation
and detachment of keratinocytes from the underlying base-
ment membrane triggers terminal di¡erentiation [1,2]. The
keratinocytes with the highest proliferative potential, the
stem cells, have higher surface levels of L1 integrins than
keratinocytes of lower proliferative potential and elevated in-
tegrin expression is required for maintenance of the stem cell
compartment [3,4].
Keratinocytes in the basal layer of human epidermis express
several integrins constitutively, including K2L1, a collagen re-
ceptor, and K3L1 and K6L4, which are laminin receptors [5].
In addition at least two integrins which are expressed either at
low levels or not at all in normal epidermis are upregulated
when keratinocytes become hyperproliferative, for example
during wound healing, in psoriasis or when keratinocytes
are placed in culture: these are K5L1, the classical ¢bronectin
receptor, and KvL6, which may be a receptor for vitronectin,
¢bronectin and tenascin [6^8]. Normally integrin expression is
downregulated during keratinocyte terminal di¡erentiation;
however, suprabasal expression is a feature of hyperprolifer-
ative epidermis and some keratinocyte tumours [5]. Modelling
in transgenic mice has shown that suprabasal integrin expres-
sion can contribute directly to the psoriatic phenotype [9].
In order to identify the basis for the regulated expression of
the K2L1 and K5L1 integrins in keratinocytes we have ana-
lysed the proximal regulatory regions of the K2 and K5 integ-
rin genes. The proximal regulatory regions of a number of
integrin K subunit genes have already been isolated and func-
tionally characterised [10^17]. In most cases their respective
promoters lack TATA boxes and are dependent on proximal
Sp1 binding sites for basal and regulated activity [18^21]. A
number of additional transcription factors have been shown
to participate in the transcription of the CD11b (PU.1) [22],
CD11c (AP-1, CCAAT/enhancer binding protein (C/EBP),
PU.1) [23^25], K2 (NF-UB) [26] and K4 (ZEB) [27] integrins.
In this report we highlight the importance of C/EBPs in the
inhibition of K2 and K5 integrin gene transcription that occurs
during keratinocyte terminal di¡erentiation and present evi-
dence that AP-1 factors play a role in the selective upregula-
tion of the K5 gene observed in hyperproliferative epidermis.
2. Materials and methods
2.1. Cell culture
Normal human keratinocytes (strains ka, kc, kq and kz; passage
numbers 2^7), derived from neonatal foreskin, were cultured in the
presence of a feeder layer of mitomycin C-treated J2-3T3 cells [28] and
suspension-induced di¡erentiation was carried out as described previ-
ously [29]. For transfection experiments, keratinocytes were grown in
keratinocyte serum-free medium (KSFM; Gibco), supplemented with
recombinant epidermal growth factor (rEGF), bovine pituitary extract
and gentamicin, as recommended by the manufacturer. The human
cell lines HepG2 (hepatoma) and U937 (monoblastic leukaemia) were
cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM) and
RPMI, respectively, supplemented with 10% FCS, 2 mM glutamine,
and 50 mg/ml gentamicin.
2.2. Reporter plasmid construction
The pGL2-derived p173-Luc and p27-Luc plasmids, where lucifer-
ase expression is driven by the 3173/+23 or the 327/+23 fragments
from the K5 integrin gene promoter, were kindly provided by Dr T.
Birkenmeier (Washington University). To synthesise the K5 promoter
fragment spanning 392/+23, a Pfu polymerase-mediated PCR proto-
col was performed with the oligonucleotides 392/+23 (sense) and +23/
346 (antisense), whose 16 3P nucleotides are complementary. The
PCR protocol included a 5 min denaturation step at 95‡C, followed
by a 15 min extension step at 72‡C and a 35 cycle PCR procedure
(1 min at 95‡C, 30 s at 50‡C, and 1 min at 72‡C). An identical
approach was used to synthesise the 392/+23 K5 promoter fragment
harbouring mutations at the C/EBP binding site (TTTGGCAA mu-
tated to GACTAGTC) or the AP-1 binding site (TGAGTCA mutated
to TGCAGCA). In all cases the sense oligonucleotides contained a
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BglII restriction site at their 5P ends while the +23/346 oligonucleo-
tide contained a HindIII site at its 5P end. The resulting PCR products
were digested with BglII and HindIII and the fragments puri¢ed and
ligated into BglII/HindIII-digested pGL3 plasmid (Promega). In the
case of the K2 integrin, the promoter region between 392 and +109
was synthesised by PCR using the K2 integrin promoter-based report-
er plasmid p900bp-CAT (kindly provided by Dr M. Zutter, Washing-
ton University School of Medicine) as template. The primer oligonu-
cleotides 392/357 and +109/390 were designed to contain BglII and
HindIII sites, respectively, and the resulting PCR fragments were in-
serted into BglII/HindIII-digested pGL3. An identical strategy was
used to replace the C/EBP binding site TTGCGGAA at 372 by the
sequence GACTAGTC, which has been previously demonstrated to
prevent C/EBP binding [24]. Insertion of the K2 and K5 regulatory
sequences in the pXP2 reporter construct [30] was accomplished by
recovery of the 392/+25 (K5) or 392/+109 (K2) fragments from the
pGL3-based plasmids after digestion with BglII and HindIII, and
later insertion of the isolated fragments into BamHI/HindIII-digested
pXP2, to yield the plasmids pA5-92-Luc, pA5-92(CEBPmut)-Luc,
pA5-92(AP1mut)-Luc, pA2-92-Luc and pA2-92(CEBPmut)-Luc. All
constructs were con¢rmed by sequencing.
2.3. Transfection
Keratinocytes (2.5^3.5U105/35 mm dish) were seeded in KSFM the
day before transfection. DNA (2 Wg) was diluted in 100 Wl of serum-
and antibiotic-free DMEM in polystyrene tubes. 10 Wl of Superfect
reagent (Qiagen) was added and the mixture was vortexed and incu-
bated for 15 min at room temperature. Finally, 600 Wl of KSFM was
added to the mixture. After washing with phosphate-bu¡ered saline
(PBS), keratinocytes were incubated with the DNA^reagent mix for
3 h at 37‡C, washed once with PBS and cultured for 24 h in 2 ml of
KSFM. In transactivation experiments using the CMV promoter-
based C/EBP expression vectors (CMV-0, CMV-CEBPK and CMV-
CEBPL, kindly provided by Dr G.J. Darlington, Texas Children’s
Hospital, USA), 1.6 Wg of luciferase reporter construct was cotrans-
fected with 0.4 Wg of the corresponding expression vectors. Transfec-
tion of HepG2 cells was carried out using an identical protocol but
plating 4U105 cells per well. Cells were usually cultured for 24^48 h,
washed and processed for luciferase activity measurement. For com-
parative purposes between cell lines and reporter gene constructs,
transfection e⁄ciencies were normalised by cotransfection with the
L-galactosidase expression plasmid pCMV-Lgal. The activity of each
reporter construct was expressed relative to the activity produced by
the pCMV-Lgal plasmid (relative light units).
2.4. Electrophoretic mobility shift assays (EMSA)
EMSA were performed essentially as described [23^25]. Unlabeled
competitor oligonucleotides were added to the nuclear extracts at a
100-fold molar excess. Nuclear extracts were prepared as described
previously [31], except that aprotinin, antipain, leupeptin, pepstatin
(1 mg/ml) and 10 WM Pefabloc (Boehringer Mannheim) were included
as additional protease inhibitors. The K2 and K5 integrin promoter-
based oligonucleotides used for EMSA and their relative positions are
shown in Fig. 1.
Additional double-stranded oligonucleotides used as competitors
and/or probes included AP1CONS (5P-CGCTTGATGAGTCAGC-
CGGAA-3P), Sp1CONS (5P-ATTCGATCGGGGCGGGGCGAGC-
3P), CEBPCONS (5P-TGCAGATTGCGCAATCTGCA-3P) and CEB-
PCONS-mut (5P-TGCAGAGACTAGTCTCTGCA-3P), which con-
tain the consensus binding sites for AP-1, Sp1, C/EBP, and a mutated
C/EBP consensus binding site, respectively. The CD11c promoter-de-
rived oligonucleotides used were Sp1-CD11c (Sp1-70 in [19]) (5P-
GCGTACTCTGCCCGCCCCCTCTGACTC-3P) ; Sp1mut-CD11c
(Sp1-70mut in [19]) (5P-GCGTACTCTGCCCGAATTCCTCTGAC-
TC-3P) ; AP1-CD11c (AP1-60 in 23) (5P-GCCCCCTCTGACT-
CATGCTGACAA-3P) ; AP1mut-CD11c (AP1-60mut in [23]) (5P-
GCCCCCTCTGCAGCATGCTGACAA-3P) ; CEBP-CD11c (Box D
in [24]) (5P-CCTCGGATCAGTTGCGTACTCTGCC-3P) ; CEBP-
mut-CD11c (Box Dmut4 in [24]) (5P-CCTCGGATCAGGACTAG-
TCTCTGC-3P).
2.5. Western blotting
Proteins from nuclear extracts (10^15 Wg) were subjected to SDS^
PAGE under reducing conditions and transferred onto an Immobilon
polyvinylidene di£uoride membrane (Millipore, Bedford, MA, USA).
After blocking unoccupied sites with TBS bu¡er (100 mM NaCl, 10
mM Tris pH 7.4) containing 5% of non-fat dry milk, protein detection
was performed using the Amersham ECL protocol according to the
manufacturer’s instructions. For reprobing, membranes were incu-
bated 2U30 min in stripping bu¡er (0.2 M glycine, pH 2.2, 0.1%
sodium dodecyl sulfate, 1.0% Tween-20) at 50‡C, followed by thor-
ough washes with blocking bu¡er.
3. Results
3.1. A common structure in the proximal regulatory regions of
the CD11c, K2 and K5 integrin genes: presence of
functional Sp1, AP-1 and C/EBP binding sites
Analysis of the leukocyte integrin gene CD11c has demon-
strated the involvement of the AP-1 and C/EBP transcription
factor families in its tissue-speci¢c and di¡erentiation-regu-
lated expression [23,24]. To ¢nd out whether these factors
participate in the transcription of the K2 and K5 integrin genes
in keratinocytes we compared the regulatory regions of the
CD11c, K2 and K5 integrin genes. Alignment of the three
proximal promoter sequences revealed homologous Sp1 bind-
ing sites 60^70 nucleotides upstream of the major transcrip-
tional start sites (Fig. 1), two of which (CD11c-Sp1-70 and
Fig. 1. Alignment of the proximal regulatory regions of the K2, K5 and CD11c integrin genes. Identi¢ed and putative cis-acting elements are
boxed, and their positions are shown relative to their respective major transcriptional start sites. Oligonucleotides used for EMSA are indicated
below the respective sequences.
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K2-56) are known to be absolutely required for optimal activ-
ity of their respective promoters [19^21]. A perfect consensus
sequence for AP-1 binding was found at 350 within the K5
promoter (K5-AP1-50), in the same relative location as the
AP-1 binding site which controls the di¡erentiation respon-
siveness of the CD11c promoter [23]. In addition, putative C/
EBP binding sites were identi¢ed within the K2 (372) and K5
(370) promoters, and their location was homologous to that
of the previously reported C/EBP binding site in the CD11c
promoter [24] (Fig. 1). The putative C/EBP binding site in the
K2 promoter very closely resembled the C/EBP binding con-
sensus element (A/GTTGCGT/CAAT/C) [32] (eight identical
residues out of 10), while that in the K5 promoter exhibited a
lower degree of identity (6/10 nucleotides) (Fig. 1).
32P-labelled oligonucleotides spanning each of the putative
cis-acting elements were assayed by EMSA. 100-fold molar
excess of each corresponding cold oligonucleotide prevented
the formation of all the observed complexes, demonstrating
the speci¢city of the assay (Fig. 2 and data not shown). The
element at 360 in the K5 promoter (hereafter named K5-Sp1-
60) was recognised by Sp1 and Sp1-related factors since the
retarded complex was competed by consensus Sp1 binding
sequences and by the previously described K2-Sp1-56 and
CD11c-Sp1-70 elements [31,34], but not by an oligonucleotide
containing a mutated Sp1 site (Fig. 2A). The element at 350
in the K5 promoter (hereafter named K5-AP1-50) was recog-
nised by the AP-1 transcription factor family: formation of
the retarded complexes was abrogated in the presence of bona
¢de AP-1 binding sequences (including the CD11c-60-AP1
element from the CD11c promoter) or anti-c-Jun or anti-c-
Fos antisera, but not by a mutated AP-1 site or by anti-JunB
(Fig. 2B). The elements at 372 in the K2 promoter and 370 in
the K5 promoter (hereafter named K2-CEBP-72 and K5-
CEBP-70) were recognised by C/EBP-related factors, as the
retarded complexes were inhibited by a consensus C/EBP oli-
gonucleotide or the C/EBP site from the CD11c promoter
(CD11c-CEBP-80) [34], but were una¡ected in the presence
of a mutated C/EBP recognition site or by a mutation of
CD11c-CEBP-80 which prevents C/EBP binding (Fig. 2C
and data not shown).
We conclude that the proximal promoter regions of the K2,
K5 and CD11c integrin genes have a highly conserved struc-
ture, with similarly positioned Sp1 and C/EBP binding sites.
The K5 and CD11c promoters share, in addition, an AP-1
binding site downstream of the Sp1 element.
3.2. Recognition of the K2-CEBP-72, K5-AP1-50 and
K5-CEBP-70 elements during suspension-induced
terminal di¡erentiation
Suspension-induced terminal di¡erentiation of cultured pri-
mary keratinocytes constitutes a very useful model for study-
ing how integrin expression is downregulated during di¡er-
entiation [29]. After 5 h in suspension, keratinocytes
withdraw from the cell cycle and commit to terminal di¡er-
entiation; at this time surface integrin levels do not decrease
but the receptors lose their ligand binding ability [29,33]. After
24 h in suspension transcription of integrin genes is inhibited,
integrins are lost from the cell surface and expression of di¡er-
entiation markers such as involucrin is induced [29,33]. To
analyse the functional signi¢cance of the Sp1, AP1 and
C/EBP integrin promoter elements in keratinocytes, EMSA
was performed using nuclear extracts from adherent, prolifer-
ating keratinocytes or cells that had been placed in suspension
for up to 24 h to induce di¡erentiation.
As shown in Fig. 2A the K5 Sp1 site still gave rise to
retarded complexes after 24 h in suspension. The K5-AP1-50
element also gave rise to retarded complexes with nuclear
extracts from both adherent (0 h in suspension) and di¡er-
entiating (5 or 24 h in suspension) keratinocytes. The forma-
tion of the retarded complexes on K5-AP1-50 was inhibited by
AP-1 consensus sequences or by antisera against c-Jun and c-
Fos. We conclude that the K5-AP1-50 element is mainly rec-
ognised by c-Jun/c-Fos dimers in keratinocytes and that its
occupancy is not altered during suspension-induced di¡eren-
tiation.
Fig. 2. Speci¢city and characterisation of EMSA complexes formed
on the K5-Sp1-60, K5-AP1-50, K5-CEBP-70 and K2-CEBP-72 ele-
ments. Nuclear extracts from primary keratinocytes, either adherent
(0 h) or after 5 or 24 h of suspension-induced di¡erentiation, were
tested for their capacity to recognise the K5-Sp1-60 (A), K5-AP1-50
(B), K5-CEBP-70 and K2-CEBP-72 (C) elements. The speci¢city of
the interactions was determined in the presence of either a 100-fold
molar excess of the indicated competitor oligonucleotides or antisera
against members of the C/EBP family (C/EBPK, L and O) or AP-1
family (c-Fos, c-Jun and JunB).
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EMSA analysis of the K2-CEBP-72 and K5-CEBP-70 ele-
ments using keratinocyte nuclear extracts revealed formation
of speci¢c retarded complexes which were competed by con-
sensus C/EBP binding oligonucleotides (Fig. 2C), demonstrat-
ing that C/EBP-related factors bound both elements. More-
over, comparison of the EMSA pattern produced by nuclear
extracts from adherent and di¡erentiating cells showed a
change in the mobility of the retarded complexes, a shift
which was more obvious in the case of the K2-CEBP-72 site
(Fig. 2C). With nuclear extracts from adherent keratinocytes
an antiserum against C/EBPL abrogated the formation of
complexes on the K2-CEBP-72 and K5-CEBP-70 elements,
while C/EBPK-speci¢c antiserum had no e¡ect (Fig. 2C and
data not shown); this indicates that most complexes in adher-
ent keratinocytes were composed of C/EBPL dimers. In con-
trast, the retarded bands obtained with nuclear extracts of
di¡erentiating keratinocytes were greatly a¡ected by the pres-
ence of C/EBPK-speci¢c antiserum, the antiserum to CEBPL
having a somewhat lower e¡ect (Fig. 2C). Antisera against
C/EBPN and C/EBPO had no e¡ect on complex formation in
either adherent or suspended keratinocytes (Fig. 2C and data
not shown).
We conclude that both K2-CEBP-72 and K5-CEBP-70 are
recognised by members of the C/EBP transcription factor
family in keratinocytes and that the factors that bind to
them are altered during terminal di¡erentiation. Only
C/EBPL was found in retarded complexes from adherent ker-
atinocytes while both C/EBPK and C/EBPL could be observed
in the complexes from di¡erentiating cells. The complexes in
di¡erentiating cells could potentially be C/EBPK dimers or C/
EBPK-CEBPL heterodimers.
3.3. Role of the K2-CEBP-72, K5-AP1-50 and K5-CEBP-70
elements in integrin promoter activity
Since expression of the K2 and K5 integrins in keratinocytes
is di¡erentiation- and, in the case of K5, activation-dependent
we analysed the activity of their corresponding promoters in
cultured primary human keratinocytes. K2 and K5 promoter-
based plasmids were constructed that included the regions
392/+23 of the K5 promoter or 392/+109 of the K2 promoter
in front of a luciferase reporter gene (plasmids A2-92-Luc and
A5-92-Luc; Fig. 3A). Transient transfection of the A2-92-Luc
and A5-92-Luc reporter constructs showed that both pro-
moters were active in primary human keratinocytes, with ac-
tivities ranging between 10 and 250 times higher than that of
the promoterless plasmid pXP2 (Fig. 3B). The activity of A2-
92-Luc was usually 2^5 times higher than that of A5-92-Luc
(Fig. 3B). Therefore, the K2 and K5 proximal promoters had
transcriptional activity in keratinocytes.
To determine the role of the K2-CEBP-72, K5-AP1-50 and
K5-CEBP-70 sequence elements, each one was disrupted by
introducing mutations known to prevent recognition by ei-
ther AP-1 or C/EBP factors. The resulting promoter con-
structs A2-92(CEBPmut)-Luc, A5-92(AP1mut)-Luc and A5-
92(CEBPmut)-Luc were analysed by transient transfection in
primary keratinocytes (Fig. 3A,B). Disruption of the K5-AP1-
50 element had a profound e¡ect on the activity of the K5
promoter, as it lowered its activity to 15^20% of the wild-type
Fig. 3. Activity of the K2 and K5 integrin gene promoter regions in primary human keratinocytes. A: Schematic representation of the wild-type
and mutated K2 and K5 integrin promoter constructs. Wild-type cis-acting elements are indicated by ¢lled dots, while mutated elements are de-
picted as empty circles. B: Primary human keratinocytes were transfected with the indicated reporter constructs and luciferase activity deter-
mined after 24^30 h. In all experiments, each plasmid was transfected at least ¢ve times, with at least two distinct DNA preparations, and
transfections were performed in the presence of pCMV-Lgal plasmid to normalise the transfection e⁄ciency. Two independent experiments are
shown.
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values (Fig. 3B), indicating that AP-1 transcription factors
positively contribute to transcription of the K5 integrin gene.
Mutation of the K5-CEBP-70 site lowered the activity of the
K5 promoter between 30 and 60%, with the activity of A5-
92(CEBPmut)-Luc being on average 68% of that of A5-92-
Luc (Fig. 3B), suggesting that C/EBP factors also contribute
positively to transcription of the K5 gene.
Disruption of the K2-CEBP-72 C/EBP binding site caused
an increase in the activity of the K2 promoter, which was 2.6-
fold on average and in some experiments was as high as 13-
fold (Fig. 3B). The C/EBP binding site therefore acted as a
negative regulatory element within the K2 promoter. A similar
increase was observed after transfection of the mutated K2
promoter in Jurkat lymphoblastic cells and in bovine aortic
endothelial cells (data not shown), indicating that the K2-
CEBP-72 element decreases the activity of the K2 promoter
in distinct cell lineages. Therefore, the C/EBP binding sites
within the K2 and K5 proximal regulatory regions mediate
opposite transcriptional activities on the respective promoters.
3.4. In£uence of C/EBPK and C/EBPL overexpression on
K2 and K5 integrin promoter activity
Having demonstrated that the C/EBP binding sites contrib-
uted to the activity of the K2 and K5 integrin proximal pro-
moters we investigated the e¡ects of elevated expression of
C/EBP factors on promoter activity. Each promoter construct
was co-transfected with expression vectors for C/EBPK and
C/EBPL into adherent primary human keratinocytes. Expres-
sion of either C/EBPK or C/EBPL caused a dramatic decrease
in the activity of the K2 proximal promoter, reducing activity
more than eight-fold (Fig. 4A). The same e¡ect was observed
with the A2-92(CEBPmut)-Luc construct, showing that the
repressor e¡ect of C/EBP factors was independent of occu-
pancy of the K2-CEBP-72 element. Analysis of the K5 pro-
moter constructs revealed a similar decrease on cotransfection
with C/EBPK or C/EBPL (Fig. 4A). In both integrin pro-
moters, C/EBPK was a more e¡ective repressor than
C/EBPL (Fig. 4A).
To examine how general the transcriptional repression by
C/EBP factors was we also transfected the hepatoma cell line
HepG2, where C/EBP-dependent transactivation can be read-
ily demonstrated [34,35]. In contrast to their activity in human
keratinocytes, the basal activity of the A2-92-Luc or A5-92-
Luc constructs was almost undetectable, with luciferase activ-
ity values very close to those produced by the promoterless
pXP2 plasmid (Fig. 4B). Cotransfection of either C/EBP ex-
pression vector led to a marked increase in the activity of both
integrin promoters, C/EBPK-mediated transactivation usually
being ¢ve times higher than that mediated by C/EBPL (Fig.
4B). C/EBPK and C/EBPL transactivated the A2-92-Luc con-
struct 60- and 15-fold, respectively (Fig. 4B).
Both C/EBP factors signi¢cantly transactivated the K5 pro-
moter constructs in HepG2 cells, albeit to a lower extent than
the K2 constructs. C/EBPK cotransfection produced a 20-fold
increase in the activity of the proximal K5 promoter, while
C/EBPL augmented the activity three-fold (Fig. 4B). Mutation
of K5-CEBP-70 or K2-CEBP-72 decreased C/EBPK- or
C/EBPL-mediated transactivation by 30^40% (Fig. 4B), sug-
gesting the presence of additional elements mediating the
C/EBP transcriptional e¡ect. The C/EBP-mediated transacti-
vation of A5-92(AP1mut)-Luc was usually higher than of the
wild type or A5-92(CEPmut)-Luc construct, indicating that
occupancy of the AP-1 binding site contributes to the e¡ect
of C/EBP factors on the K5 promoter.
In summary, transactivation experiments demonstrated that
C/EBPK and C/EBPL di¡erentially a¡ected the activity of the
K2 and K5 promoters in distinct cell lineages, repressing in
human keratinocytes and activating in hepatoma cells. The
repressive e¡ects of C/EBP factors in keratinocytes were not
mediated by the identi¢ed C/EBP binding sites.
Fig. 4. Contribution of the K5-AP1-50, K5-CEBP-70 and K2-CEBP-
72 elements to the activity of the proximal K5 and K2 integrin pro-
moters. Primary human keratinocytes (A) or HepG2 cells (B) were
transfected with the indicated reporter constructs in the presence of
either an empty vector (CMV-0), or expression vectors for C/EBPK
(CMV-C/EBPK) or C/EBPL (CMV-C/EBPL), and luciferase activity
was determined after 24^30 h. In all experiments each plasmid was
transfected at least three times, with two distinct DNA preparations,
and transfections were performed in the presence of pCMV-Lgal
plasmid to normalise the transfection e⁄ciency.
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3.5. Detection of C/EBPK and C/EBPL in nuclear extracts of
di¡erentiating keratinocytes
The presence of C/EBP factors in the nuclei of cultured
primary human keratinocytes and their e¡ects on the proxi-
mal regulatory regions of the K2 and K5 integrin genes
prompted us to analyse their expression during suspension-
induced terminal di¡erentiation, using U937 cells as a positive
control. In agreement with the EMSA results (Fig. 2C), West-
ern blotting of nuclear proteins showed that C/EBPL was
highly expressed in the nuclei of adherent keratinocytes and
its expression was maintained during suspension-induced dif-
ferentiation (Fig. 5). C/EBPK was not detected in the nucleus
of adherent cells but was present in cells that were undergoing
terminal di¡erentiation after 24 h in suspension (Fig. 5). Both
the 42 and 30 kDa isoforms of C/EBPK were found in the
nuclei of di¡erentiating keratinocytes (Fig. 5). Therefore, ex-
pression of C/EBPK was speci¢cally induced during terminal
di¡erentiation, in agreement with the detection of C/EBPK-
containing EMSA complexes exclusively in di¡erentiated ker-
atinocytes.
4. Discussion
Our results suggest possible mechanisms by which K2 and
K5 integrin gene expression is downregulated during epider-
mal terminal di¡erentiation and expression of the K5 integrin
gene is upregulated in hyperproliferative epidermis. The K5
proximal promoter has an AP-1 site that is absent from the
K2 promoter and this site contributed positively to K5 pro-
moter activity. We propose that upregulation of AP-1 expres-
sion in response to growth factors [36] would contribute to
activation of K5 when keratinocytes are stimulated to prolif-
erate, for example in culture or during wound healing. Indeed,
serum addition is capable of increasing the activity of the K5
promoter in keratinocytes, and preliminary experiments indi-
cate that EGF also increases K5 integrin promoter activity
(data not shown). Conversely, C/EBPK and C/EBPL nega-
tively regulate the activity of the K2 and K5 integrin pro-
moters in keratinocytes and expression of these transcription
factors is upregulated during terminal di¡erentiation in the
epidermis [37^39].
The position and spacing of the Sp1, AP-1 and C/EBP
binding sites within the K5 proximal promoter were identical
to the CD11c integrin promoter where a composite element
(CESpAP) that includes all three sites mediates the C/EBP
transcriptional e¡ect [24]. Although an AP-1 site was lacking
in the K2 promoter the Sp1 and C/EBP sites were conserved,
as previously reported [20,21]. The almost identical arrange-
ment of cis-acting elements within the K2, K5 and CD11c
proximal promoters points to the existence of shared mecha-
nisms for coupling integrin transcription to the state of cellu-
lar di¡erentiation/activation in distinct cellular backgrounds.
In normal human epidermis both C/EBPK and C/EBPL are
induced during terminal di¡erentiation [37^39]. C/EBPK was
also induced during terminal di¡erentiation of cultured kera-
tinocytes in suspension, but functional C/EBPL was consti-
tutively expressed, showing that C/EBPL expression is com-
patible with keratinocyte proliferation. The expression of
C/EBPL can be induced by numerous factors, including
growth factors (EGF) and hormones (insulin) [40,41] that
are present in keratinocyte culture medium. Overexpression
of C/EBP factors can contribute to keratinocyte growth arrest
and di¡erentiation; this could be through their capacity to
enhance p21 expression and function [42^44], but also
through their ability to downregulate integrin expression [1,4].
The proximal K2 and K5 integrin promoters exhibited some
cell type-speci¢c activity, as shown by the functional analysis
in distinct cell types (HepG2 and keratinocytes). Both regu-
latory regions were active in keratinocytes while their activity
was virtually undetectable in hepatoma cells. Overexpression
of either C/EBPK or C/EBPL transactivated the promoters in
HepG2 cells, but repressed promoter activity in keratinocytes.
The repressive e¡ect of overexpressing C/EBPK or C/EBPL in
keratinocytes did not depend on the C/EBP sites in either
promoter. The in£uence of C/EBP factors on the integrin
promoters resembles the cell type-dependent activity that
C/EBPL has on the upstream regulatory region (URR) of
human papillomavirus type 18 [45,46]. C/EBPL transactivates
the URR in HepG2 cells, while it represses its activity in
epithelial (HeLa) cells in a DNA binding-independent manner
through its interactions with the YY-1 transcription factor.
Since YY-1 is an initiator binding protein [47] and integrin
promoters exhibit initiator-like sequences at their major tran-
scriptional start sites [10,13], it is tempting to speculate that a
similar mechanism could also exist in keratinocytes.
Given the broad range of transcription factors known to
physically interact with C/EBP factors (Sp1, AML1, c-Myb,
NF-UB, c-Jun or E47 [48^53]), C/EBP-mediated repression of
the integrin promoters in keratinocytes might also be exerted
by interfering with the functional activity of transcription fac-
tors whose binding sites are adjacent to those of C/EBP. The
presence of the AP-1 site in the K5 promoter might thus ex-
plain why although mutation of the C/EBP site in the K2
promoter led to a large increase in promoter activity, this
was not the case when the same site in the K5 promoter was
mutated.
Previous studies have suggested a link between adhesion to
extracellular matrix and the expression of the distinct C/EBP
proteins. In adipocytes, adhesion to di¡erent extracellular sur-
faces a¡ects the pattern of C/EBP factor expression [54], and a
C/EBPL binding site is located within the extracellular matrix-
Fig. 5. Expression of C/EBPK and C/EBPL during suspension-in-
duced di¡erentiation of primary human keratinocytes. Nuclear ex-
tracts from myeloid U937 cells and keratinocytes (kq, passage 6)
placed in suspension for 0 (kq6 0h), 5 (kq6 5h) or 24 h (kq6 24h)
to induce terminal di¡erentiation, were subjected to SDS^PAGE,
transferred to Immobilon membranes and incubated with antisera
against C/EBPK or C/EBPL (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA). The positions of the C/EBPK isoforms (K42 and
K30) are indicated.
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responsive enhancer in the bovine L-casein gene [55]. When
keratinocytes become committed to di¡erentiate the integrins
on the cell surface lose ligand binding activity [33] and it is
possible that the subsequent detachment of keratinocytes from
the underlying basement membrane is the stimulus for induc-
tion of C/EBPK and C/EBPL in vivo; this in turn would lead
to downregulation of integrin expression. It will be of interest
to test this hypothesis and also to analyse whether C/EBP
expression is downregulated in hyperproliferative epidermis,
where suprabasal integrin expression is observed [5,9].
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